156 related articles for article (PubMed ID: 33101460)
1. HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primary CNS lymphoma: a single center series.
Seidel S; Kowalski T; Margold M; Baraniskin A; Schroers R; Martus P; Schlegel U
Ther Adv Neurol Disord; 2020; 13():1756286420951087. PubMed ID: 33101460
[TBL] [Abstract][Full Text] [Related]
2. HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis.
Seidel S; Korfel A; Kowalski T; Margold M; Ismail F; Schroers R; Baraniskin A; Pels H; Martus P; Schlegel U
Neurol Res Pract; 2019; 1():17. PubMed ID: 33324883
[TBL] [Abstract][Full Text] [Related]
3. Complications of intracerebroventricular chemotherapy via subgaleal reservoir in primary central nervous system lymphoma: A single-institution experience on 1247 installations in 94 consecutive patients.
Anton S; Margold M; Kowalski T; Miller D; Schmieder K; Schlegel U; Seidel S
Hematol Oncol; 2021 Apr; 39(2):176-184. PubMed ID: 33316084
[TBL] [Abstract][Full Text] [Related]
4. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study.
Pels H; Juergens A; Glasmacher A; Schulz H; Engert A; Linnebank M; Schackert G; Reichmann H; Kroschinsky F; Vogt-Schaden M; Egerer G; Bode U; Schaller C; Lamprecht M; Hau P; Deckert M; Fimmers R; Bangard C; Schmidt-Wolf IG; Schlegel U
J Neurooncol; 2009 Feb; 91(3):299-305. PubMed ID: 18931887
[TBL] [Abstract][Full Text] [Related]
5. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
6. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
Pels H; Schmidt-Wolf IG; Glasmacher A; Schulz H; Engert A; Diehl V; Zellner A; Schackert G; Reichmann H; Kroschinsky F; Vogt-Schaden M; Egerer G; Bode U; Schaller C; Deckert M; Fimmers R; Helmstaedter C; Atasoy A; Klockgether T; Schlegel U
J Clin Oncol; 2003 Dec; 21(24):4489-95. PubMed ID: 14597744
[TBL] [Abstract][Full Text] [Related]
7. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study.
Schlegel U; Pels H; Glasmacher A; Kleinschmidt R; Schmidt-Wolf I; Helmstaedter C; Fliessbach K; Deckert M; Van Roost D; Fimmers R; Bode U; Klockgether T
J Neurol Neurosurg Psychiatry; 2001 Jul; 71(1):118-22. PubMed ID: 11413277
[TBL] [Abstract][Full Text] [Related]
8. Successful Use of High Dose Methotrexate in Treatment of Primary CNS Lymphoma Patients Without Access to Serum Methotrexate Levels Monitoring: Challenges and Outcome.
Singh C; Jain A; Takkar A; Agarwal A; Rohilla M; Lad D; Khadwal A; Basher R; Radotra BD; Bal A; Das A; Gupta V; Lal V; Varma S; Malhotra P; Prakash G
Indian J Hematol Blood Transfus; 2022 Jan; 38(1):68-77. PubMed ID: 35125713
[TBL] [Abstract][Full Text] [Related]
9. Primary central nervous system lymphoma: a single-centre experience of 55 unselected cases.
Hodson DJ; Bowles KM; Cooke LJ; Kläger SL; Powell GA; Laing RJ; Grant JW; Williams MV; Burnet NG; Marcus RE
Clin Oncol (R Coll Radiol); 2005 May; 17(3):185-91. PubMed ID: 15901003
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma.
Villanueva G; Guscott M; Schaiquevich P; Sampor C; Combs R; Tentoni N; Hwang M; Lowe J; Howard S
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900250
[TBL] [Abstract][Full Text] [Related]
11. Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome.
Seidel S; Margold M; Kowalski T; Baraniskin A; Schroers R; Korfel A; Thiel E; Weller M; Martus P; Schlegel U
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208229
[TBL] [Abstract][Full Text] [Related]
12. Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort.
Yerram P; Reiss SN; Modelevsky L; Schaff L; Reiner AS; Panageas KS; Grommes C
Ann Lymphoma; 2023 Feb; 7():. PubMed ID: 37067886
[TBL] [Abstract][Full Text] [Related]
13. Primary Central Nervous System Lymphoma: Clinical Characteristics, Treatment Options and Therapeutic Outcome in 36 Patients. A Single Center Experience.
Zektser M; Rabinovich A; Grinbaum U; Porges T; Gozlan A; Gourevitch A; Al-Athamen K; Barrett O; Peles I; Kaisman-Elbaz T; Levi E
Isr Med Assoc J; 2022 Oct; 24(10):654-660. PubMed ID: 36309861
[TBL] [Abstract][Full Text] [Related]
14. Outcome and prognostic factors of very old patients with primary CNS lymphoma: a retrospective analysis of patients ≥80 years treated with high-dose methotrexate-based chemotherapy.
Seidel S; Kowalski T; Nilius-Eliliwi V; Schroers R; Schlegel U
Leuk Lymphoma; 2022 Dec; 63(12):2905-2911. PubMed ID: 35856480
[TBL] [Abstract][Full Text] [Related]
15. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
[TBL] [Abstract][Full Text] [Related]
16. Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma.
Seidel S; Pels H; Schlömer S; Kowoll A; Fliessbach K; Engert A; Vogt-Schaden M; Egerer G; Reichmann H; Schackert G; Kroschinsky F; Deckert M; Herrlinger U; Klockgether T; Fimmers R; Bode U; Schmidt-Wolf IGH; Schlegel U
Neurology; 2020 Dec; 95(23):e3138-e3144. PubMed ID: 32989105
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
18. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
[TBL] [Abstract][Full Text] [Related]
19. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]